Health Care • Biotechnology: Pharmaceutical Preparations
$1.93 ▼ -0.13
(-6.31%)
MKT CAP: $131.3M • VOL: 524.1K
52W L $0 52W H $3
ROARABLE / RQD
D- • 40/100
PIOTROSKI
1 / 9
HURA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $0 | $0 | $0 |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$31.0M | -$23.0M | -$15.0M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$27.6M | -$14.7M | -$12.0M |
| Capital Expenditures (CapEx) | $76.1K | $57.9K | — |
| Free Cash Flow (FCF) | -$27.7M | -$14.8M | -$12.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | — | — | — |
| Cash & Short-Term Equivalents | $3.6M | $12.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $20.9M | $14.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HURA.